Prostate Cancer Test

No sex, alcohol and other risk factors have been proven to cause a rapid development in prostate cancer, the ultimate blow that can ruin a man's sex life. Too few recover after surgery without remaining impotent. Now, a research led at Duke Prostate Center and published in the online journal Prostate shows that being a sweet tooth also harms the prostate. Tests made on lab mice underline that a decrease in insulin levels triggered by less sugars in the diet could stop tumor .

Woster: Recuperation makes me value my freedom

As I write this column, I am in my 10th day of recuperation from prostate cancer surgery and doing well, thank you.I bring this up, not to belabor the fact that I got whacked with a disease. We have already done that.I will, however, for the final time, remind all of you fellows who are over 50 to include the prostate tests in your regular physical. It can save your life.Back to recuperation.I was sent home from a Wednesday morning surgery, Friday afternoon and the rest of that day is pretty much forgotten. High test drugs and lack of sleep will do that.It was about noon on Saturday that I began to investigate the direction, which I would take for the following couple or three weeks as far as "something to do." Dr. Hofer had fairly well defined the "what to dos" and quite frankly, I don't think he worried a lot about what should we do about Jim's boredom.

Pharmacopeia Acquires Selective Androgen Receptor Modulator ('SARM ...

PRINCETON, N.J., Oct. 15 /PRNewswire-FirstCall/ -- Pharmacopeia (NASDAQ: PCOP) , an innovator in the discovery and development of novel small molecule therapeutics, today announced that it has licensed from Bristol-Myers Squibb (NYSE: BMY) a selective androgen receptor modulator (SARM) program, including a lead compound in Phase 1 clinical development and back-up compounds. PS178990 is a non-steroidal selective androgen receptor modulator, or SARM, which was designed to provide the benefits of testosterone without its unwanted side effects on prostate. The program has completed a Phase 1 single ascending dose study.

SARM agonists are a potential novel treatment for muscle wasting associated with a number of serious chronic and acute medical conditions such as surgical and severe burn recovery, end-stage renal disease and cancer- and AIDS-related cachexia.